Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment

Bone Marrow Transplantation

Volumn 21, Issue 11, 1998, Pages 1137-1143

  Yuen, K Y ^a   Woo, P C Y ^a   Hui, C H ^a   Luk, W K ^a   Chen, F E ^a   Lie, A K W ^a   Liang, R ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Allogeneic; Bacteraemia; BMT; Risk factors

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR; IMMUNOGLOBULIN;

ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER; CATHETER INFECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG TOXICITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031804650     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701246     Document Type: Article

References (25)

1. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993; 328: 1323-1332.
2. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulation leukocytes and infection in patients with acute leukemia. Ann Intern Med 1996; 64: 328-340.
3. Pizzo PA, Robichaud KJ, Wesley R et al. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. Medicine 1982; 61: 163-165.
4. Barton TD, Mindy GS. The cause of fever following resolution of neutropenia in patients with acute leukemia. Clin Infect Dis 1996; 22: 1064-1068.
5. Nosanchuk JD, Sepkowitz KA, Pearse RN et al. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1997; 18: 355-359.
6. Chiu EKW, Yuen KY, Lie AKW et al. A prospective study of symptomatic bacteraemia following platelet transfusion and of its management. Transfusion 1994; 34: 950-954.
7. Rhame FS. Prevention of nosocomial aspergillosis. J Hosp Infect 1991; 18 (Suppl. A): 466-472.
8. Chiu EKW, Yuen P, Chan TK. Bone marrow transplantation in Hong Kong. Bone Marrow Transplant 1994; 13: 713-715.
9. Murray PR, Baron EJ, Pfaller MA et al. Manual of Clinical Microbiology, 6th edn. American Society for Microbiology: Washington, DC, 1995.
10. Bauer AW, Kirby WMM, Sherris JC et al. Antibiotic susceptibility testing by a single disc method. Am J Clin Pathol 1966; 45: 493.
11. George WL, Sutter VL, Citron D et al. Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol 1979; 9: 214-219.
12. Mermel LA, McCormick RD. Springman SR et al. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters: a prospective study utilizing molecular subtyping. Am J Med 1991; 91: (Suppl 3B): 197S.
13. Woo PCY, Lo SKF, Yuen KY et al. Detection of CMV DNA in bone marrow transplant recipients: plasma versus leucocyte polymerase chain reaction. J Clin Pathol 1997; 50: 231-235.
14. Treleaven J, Barrett J. Bone Marrow Transplantation in Practice, 1st edn. Churchill Livingstone: Edinburgh, 1992, pp 11-104, 137-150.
15. Bearman SI, Appelbaum FR, Buckner CD et al. Regimenrelated toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
16. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
17. Donnelly JP. Bacterial complications of transplantation: diagnosis and treatment. J Antimicrob Chemother 1995; 36 (Suppl B): 59-72.
18. Rotstein C, Higby D, Killion K et al. Relationship of surveillence cultures to bacteremia and fungemia in bone marrow transplant recipients with Hickman or Broviac catheters. J Surg Oncol 1988; 39: 154-158.
19. Rackoff WR, Gonin R, Robinson C et al. Predicting the risk of bacteremia in children with fever and neutropenia. J Clin Oncol 1996; 14: 919-924.
20. Sinkles EA, Green WH, Wiernick PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135: 715-719.
21. Wingard JR. Infectious and noninfectious systemic consequences. Consensus development conference on oral complications of cancer therapies: diagnosis, prevention and treatment. NC1 Monogr 1990; 9: 21-26.
22. Lum LG. The kinetics of immune reconstitution after bone marrow transplantation. Blood 1987; 69: 369-380.
23. Gisselbrecht C, Prentice HG, Bacigalupo A et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696-700.
24. American Society of Clinical Oncology. Update of recommendations for the use of hemopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996; 14: 1957-1960.
25. Byrne JL, Haynes AP, Russell NH. Use of haemopoietic growth factors: commentary on the ASCO/ECOG guidelines. Blood Rev 1997; 11: 16-27.